Lyophilized mRNA COVID-19 Vaccine Shows Good Stability and Immunogenicity in Preclinical Studies Press Release

Jiangsu Ruike Biotechnology Co.
, Ltd.
(hereinafter referred to as "Reike Bio"), which is committed to focusing on the development of innovative vaccines for major diseases, announced on February 12 that its subsidiary Wuhan Ruikeji Biotechnology Co.
, Ltd.
(hereinafter referred to as "Reike Bio") Corgi Bio”) preclinical data on lyophilized mRNA COVID-19 vaccine
.

The lyophilized mRNA-LNP COVID-19 vaccine of Ruikeji Bio uses the LNP delivery system, and the self-developed freeze-drying technology achieves formulation stability at 4°C and 25°C
.

The vaccine can be stored and transported under conventional cold chain conditions, which greatly improves the accessibility of the vaccine
.

The research results have been published online on bioRxiv
.

According to the paper, Rikage Biotech has developed lyophilized mRNA-LNP vaccines against COVID-19 of the prototype strain, Delta strain and Omicron strain respectively.
The data show that the freeze-drying process does not affect the key physical and chemical indicators, biological activities and immunogens of the vaccine.
sex
.

Notably, the Delta strain lyophilized mRNA-LNP COVID-19 vaccine induced high levels of neutralizing antibodies in mice against the prototype strain and the current major global epidemic strain Omicron
.

In the hACE2 transgenic mouse challenge assay, two doses of immunization 14 days apart provided complete protection against challenge with the Delta strain
.

The new crown epidemic has ravaged the world for more than two years, and new mutant strains are constantly emerging
.

In response to the epidemic, vaccines have become the most cost-effective means that countries rely on
.

Up to now, more than 10 billion doses of the new crown vaccine have been administered worldwide, but the vaccination rate of at least one dose in low-income countries is only about 10%
.

Improving the pertinence and accessibility of vaccines requires not only the concerted efforts of countries around the world, but also the development of a new generation of safe and effective new crown vaccines that can be stably stored and transported under conventional cold chain or even de-cold chain conditions
.

Ruike Biotech has developed a lyophilized mRNA-LNP new crown vaccine through its subsidiary Ruikeji Biological, which will well meet such needs
.